Delcath Systems Inc (DCTH.OQ)
0.41USD
11:05am EDT
$0.02 (+5.71%)
$0.39
$0.39
$0.41
$0.38
42,531
250,170
$2.37
$0.35
About
Overall
| Beta: | 2.00 |
| Market Cap (Mil.): | $37.43 |
| Shares Outstanding (Mil.): | 96.73 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| DCTH.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 27.50 | 37.76 |
| EPS (TTM): | -0.79 | -- | -- |
| ROI: | -179.51 | 9.26 | 18.76 |
| ROE: | -180.52 | 12.54 | 19.59 |
REFILE-BRIEF-Delcath Systems to reduce its workforce in the United States by 20 percent
June 26 - Delcath Systems Inc : * Implemented a program to further reduce its workforce in the United States by 20% * Expects cash utilization for the fourth quarter of 2013 to be approximately $6 million to $8 million * Company's EU-based operations are not impacted by this realignment * Aim to cut expected cash burn in Q4 to approximately 50% of what it was in Q2 2012 * Source text for Eikon * Further company coverage
FDA advisers recommend against Delcath's cancer therapy
- A panel of advisers to the U.S. health regulator unanimously recommended against approving Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver, saying it was too risky.
UPDATE 2-FDA advisers recommend against Delcath's cancer therapy
May 2 - A panel of advisers to the U.S. health regulator unanimously recommended against approving Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver, saying it was too risky.
FDA advisers vote against Delcath's cancer therapy
May 2 - A panel of advisers to the U.S. health regulator said that risks outweighed the benefits in Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver.
BRIEF-Delcath Systems shares down 6.2 pct premarket
NEW YORK, April 8 - Delcath Systems Inc : * Shares down 6.2 percent in premarket trading
Competitors
| Price | Change | |
|---|---|---|
| Medtronic, Inc. (MDT.N) | $55.49 | +0.25 |
| Baxter International Inc. (BAX.N) | $72.46 | -0.58 |
| Teleflex Incorporated (TFX.N) | $79.74 | +0.31 |
| VCA Antech Inc (WOOF.OQ) | $29.31 | +0.55 |
| Haemonetics Corporation (HAE.N) | $42.34 | +0.12 |
| ICU Medical, Incorporated (ICUI.OQ) | $71.00 | -0.69 |
| Insulet Corporation (PODD.OQ) | $32.07 | +0.18 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Zacks Investment Research Inc.
|
$12.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

